Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Licenses Long QT Syndrome Test to Aussie Services Provider

NEW YORK (GenomeWeb News) - Clinical Data's PGxHealth division has inked a sub-license agreement with Australia’s Victorian Clinical Genetics Services for a test that is aimed at diagnosing a deadly heart disorder.
 
Under the non-exclusive agreement, VCGS, a subsidiary of the Murdoch Children's Research Institute, will use the PGxHealth diagnostic to test for familial long QT syndrome in Australia and in New Zealand.
 
LQTS is an inherited disorder in heart rhythm that predisposes patients to sudden fainting spells, dizziness, palpitations, seizures, and sudden death.
 
According to PGxHealth, the test can help determine whether patients are at risk of LQTS, aid diagnosis of the syndrome, and possibly guide treatment options for those who have exhibited symptoms.
 
Financial terms of the agreement were not provided.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.